ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,040.53
-0.50%
US Tech 100
20,778.00
-0.69%
다우존스 지수
44,544.66
-0.75%
Bitcoin
97,800.35
-2.85%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. NLS Pharmaceutics Ltd (NLSP)

  7. NLS Pharmaceutics Ltd (NLSP) 뉴스

NLSP

NLS Pharmaceutics (NLSP)

NLS Pharmaceutics Ltd
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NLSP
일자시간출처헤드라인심볼기업
2025/01/3121:30PR Newswire (US)Kadimastem Shareholders Approved the Merger with NLS PharmaceuticsNASDAQ:NLSPNLS Pharmaceutics Ltd
2025/01/3021:30PR Newswire (US)NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual MeetingNASDAQ:NLSPNLS Pharmaceutics Ltd
2025/01/2821:30PR Newswire (US)NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl DependenceNASDAQ:NLSPNLS Pharmaceutics Ltd
2025/01/1623:32PR Newswire (US)Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLSNASDAQ:NLSPNLS Pharmaceutics Ltd
2025/01/0821:42PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share PriNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/12/3021:30PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed MergerNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/12/0503:15PR Newswire (US)NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/2805:01Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/2705:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/1605:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/08/1505:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/07/3105:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/07/1522:16Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NLSPNLS Pharmaceutics Ltd
2024/03/1205:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/02/2406:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2024/01/1307:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/3006:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/2306:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0706:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0506:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0506:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/12/0121:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/11/1706:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/10/2605:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/10/2522:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/09/1405:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/08/3106:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/07/2105:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/07/0402:22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
2023/06/1421:38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
 검색 관련기사 보기:NASDAQ:NLSP

최근 히스토리

NYSE
MCD
McDonalds
AMEX
SPY
SPDR S&P 500
NYSE
MRK
Merck
CCOM
US500
US 500
COIN
DOGEUSD
Dogecoin
FX
USDGBP
US Dollar vs Sterling
COIN
BTCUSD
Bitcoin
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
JPM
JP Morgan Chase
COIN
XRPUSD
Ripple
NYSE
XOM
Exxon Mobil
USI
USTECH100
US Tech 100
CCOM
US100
US Tech 100
NYSE
DIS
Walt Disney
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지